Metastatic Breast Cancer

The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

Nine years of Pinktober while living with metastatic breast cancer.

After being diagnosed with cancer, I set intentions — both spiritual and practical — that helped guide me through the experience.

Patients with HER2-positive metastatic breast cancer may receive sufficient first-line treatment with Perjeta plus Herceptin without chemotherapy.

The statistics for metastatic are grim, so I made a list of my own numbers instead.

Genetic testing is the norm for cancer patients with familial history. How did I let it slip through the crack?

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

After seeing my friend get off the merry-go-round of advanced cancer treatment, I am starting to think more seriously and soberly about my next options and decisions.

Who would have thought that a small dinosaur toy helped give me the strength to fight metastatic breast cancer?

Integrating a metastatic breast cancer diagnosis with the life you have takes time and effort.

I'm thankful that I spoke up about my bone pain related to cancer metastases.

Is it always one or the other? Can good news in one person’s cancer experience do good for the community?

When I was first diagnosed, I wasn’t sure what kind of support to ask for, but now I’m thankful to have many wonderful forms of support around me.

HER3-DXd proved to be safe and efficacious in treating patients with HER3-expressing metastatic breast cancer, recent study results showed.

Sometimes, hundreds of pages of cancer information still just doesn’t connect with the person who needs it.

Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.

Here are a few ways I stay grounded throughout cancer.

I didn’t think that I’d lose my hair again after starting my latest breast cancer treatment, but I did — and with that hair loss came both new and familiar feelings.

Research backs up my personal experience regarding aging and cancer.

Orserdu demonstrated improved outcomes and quality of life for certain patients with metastatic breast cancer.

I’m working through one of the toughest times of my life. Perserverance is one of the many things that cancer has taught me.

The FDA approval of Trodelvy for patients with HR-positive, HER2-negative metastatic breast cancer provides patients with another treatment option after hormone therapy and standard chemotherapy.

After I was diagnosed with stage 4 breast cancer, clinicians told me I wouldn’t make it to my 35th birthday, but I recently did — and look forward to celebrating many more.

The new year brings reflection on living fully with cancer.

The Food and Drug Administration approved Trodelvy for patients with pretreated, unresectable HR-positive, HER2-negative metastatic breast cancer.